Skip to main content

Otulfi News

FDA Grants Interchangeable Designation to Fresenius Kabi’s Biosimilar Otulfi (ustekinumab-aauz)

LAKE ZURICH, Ill., May 19, 2025 – Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S Food and Drug Administration (FDA) designated Otulfi (u...

Monthly News Roundup - October 2024

FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...

FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara

September 30, 2024 – Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Crohn's Disease, Crohn's Disease - Acute, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, Ulcerative Colitis - Active

Otulfi patient information at Drugs.com